Thymosin alpha-1 fused to human serum albumin (HSA) achieved dramatically extended half-life while retaining immunostimulatory activity — enabling less frequent dosing for sustained immune therapy.
Key findingThymosin alpha-1 fused to human serum albumin (HSA) achieved dramatically extended half-life while retaining immunostimulatory activity — enabling les
What the researchers found
Thymosin alpha-1 fused to human serum albumin (HSA) achieved dramatically extended half-life while retaining immunostimulatory activity — enabling less frequent dosing for sustained immune therapy.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
Cancer immunology, immunotherapy : CII, 59(9), 1335-45
Citation
Chen, Jian-Hua; Zhang, Xin-Guo; Jiang, Yu-Tao; Yan, Lu-Ying; Tang, Li; Yin, Yi-Wei; Cheng, Dai-Shuang; Chen, Jing; Wang, Min. (2010). Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.. Cancer immunology, immunotherapy : CII, 59(9), 1335-45. https://doi.org/10.1007/s00262-010-0862-9